Hong Kong
Innovent’s SYCUME Meets Primary Endpoint in Phase III Trial for Inactive Thyroid Eye Disease in China
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality me...
October 12, 2026 | News
Akeso Initiates Phase III Trial of Cadonilimab for Resectable MSI-H/dMMR Colon Cancer
Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in a Phase III clinical study (COMPASSION-40/AK104-313) ev...
October 12, 2026 | News
Suzhou Ribo Life Science Submits Phase I Clinical Trial Application in EU for siRNA Obesity Therapy RBD3133
Suzhou Ribo Life Science (06938.HK) and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as "Ribo") announced the successful submission...
October 09, 2026 | News
12 Biotechs in Hong Kong's 18A Queue, and What Each Says It Will Spend the Money On
Every Hong Kong biotech applicant has to tell investors what it will do with the money it raises. On the evidence of the twelve 18A application proofs that...
October 07, 2026 | Analysis
Akeso Enrols First Patient in Global Phase III Cadonilimab Trial for Advanced Gastric Cancer
Akeso, Inc. announced that the first patient has been enrolled in COMPASSION-37 (AK104-311), a global, multicenter Phase III head-to-head trial evaluating ...
September 29, 2026 | News
XtalPi Files US FDA IND for AI-Designed Gut-Restricted Pan-TRK Inhibitor KQTD-126
This milestone marks the first IND submission from XtalPi's proprietary pipeline, recently unveiled in its interim results, validating the company's ...
September 28, 2026 | News
Sovargen Doses First Patient in Phase Ib/IIa Trial of Kazia’s Paxalisib for Rare Epilepsies
- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology,...
September 24, 2026 | News
Akeso’s Ivonescimab Shows Significant Overall Survival Benefit Over Pembrolizumab in Phase III NSCLC Trial
Akeso, Inc. announced that a pre-specified interim analysis of overall survival (OS) in the HARMONi-2 (AK112-303) trial, as assessed by the Independent Dat...
September 04, 2026 | News
Everest Medicines Secures China Approval for CARDAMYST to Treat Acute PSVT Episodes
Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, a...
September 04, 2026 | News
ASTRI, Saint Francis University Partner to Advance AI-Enabled Biomaterials and Digital Health
The Hong Kong Applied Science and Technology Research Institute (ASTRI) and Saint Francis University (SFU) have signed a Memorandum of Understanding (MoU) ...
August 26, 2026 | News
GenScript CEO Sherry Shao Sees AI-Enabled Drug Discovery as Key Growth Engine After Strong H1 2026
Adjusted net profit surges 203.3% as Gene-to-Protein generates two-thirds of GenScript Life Science Group revenue GenScript Biotech Corporation (HKEX: 154...
August 20, 2026 | Company results
Insilico Nominates AI-Designed ISM0900 as Preclinical Candidate for Cardiovascular Risk
Insilico Medicine ("Insilico"; HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, announced the nom...
August 14, 2026 | News
Ommo Technologies Raises Series A to Scale Spatial Intelligence Platform for Physical AI
VMS Group, a global alternative investment specialist, announced that its portfolio company, Ommo Technologies (Ommo), a spatial intelligence tec...
August 13, 2026 | News
Akeso Doses First Patient in Phase II Trial of AK146D1–Ivonescimab Combination for Advanced Breast Cancer
Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in a Phase II clinical study (AK146D1-202) eval...
August 11, 2026 | News
Most Read
- Can APAC Biomanufacturing Decarbonise Without Pricing Itself Out?
- The Algorithm on the GMP Floor: AI Promises a Smarter Plant. Regulators Demand the Audit Trail.
- APAC's Peptide-Capacity Gamble
- After the Rush: APAC's mRNA and Vaccine Capacity Hangover
- The Biosimilar Race: Factory to the World — or Stuck in the Copycat Economy?
- The Vein-to-Vein Problem: Can APAC's Cold Chain Carry Advanced Therapies?
- Vectors, Plasmids and the CGT Trap: APAC's Cell and Gene Therapy Ambitions Face an Upstream Bottleneck
- Can APAC Build Radioligand Therapy Before the Atoms Decay?
- The Great Biopharma Reset: 50 Developments That Changed Everything in H1 2026
- Beyond the Trial: Can Real-World Evidence Earn Regulatory Trust in APAC?
- Beyond the Obvious Giant: Where APAC's Clinical Trials Go Next
- The Frontier That Won’t Quite Arrive
Bio Jobs
- Sanofi Turns The Page As Belén Garijo Steps In And Paul Hudson Steps Out
- Global Survey Reveals Nearly 40% of Employees Facing Fertility Challenges Consider Leaving Their Jobs
- BioMed X and AbbVie Begin Global Search for Bold Neuroscience Talent To Decode the Biology of Anhedonia
- Thermo Fisher Expands Bengaluru R&D Centre to Advance Antibody Innovation and Strengthen India’s Life Sciences Ecosystem
- Accord Plasma (Intas Group) Acquires Prothya Biosolutions to Expand Global Plasma Capabilities
- ACG Announces $200 Million Investment to Establish First U.S. Capsule Manufacturing Facility in Atlanta
- AstraZeneca Invests $4.5 Billion to Build Advanced Manufacturing Facility in Virginia, Expanding U.S. Medicine Production
News
